 John Morton
Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2023 | 436 | 1.420 |
Why?
| | Immunotherapy | 2 | 2020 | 475 | 1.080 |
Why?
| | Xenograft Model Antitumor Assays | 9 | 2020 | 706 | 0.950 |
Why?
| | Bariatric Surgery | 3 | 2023 | 161 | 0.900 |
Why?
| | Disease Models, Animal | 6 | 2020 | 3542 | 0.830 |
Why?
| | Tumor Microenvironment | 4 | 2020 | 433 | 0.750 |
Why?
| | Neoplastic Stem Cells | 6 | 2020 | 334 | 0.750 |
Why?
| | Caenorhabditis elegans | 4 | 2013 | 269 | 0.730 |
Why?
| | Carcinoma, Squamous Cell | 7 | 2019 | 584 | 0.630 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 38 | 0.610 |
Why?
| | Gastric Bypass | 1 | 2019 | 92 | 0.600 |
Why?
| | Hematopoietic Stem Cells | 2 | 2018 | 345 | 0.600 |
Why?
| | Laparoscopy | 1 | 2019 | 388 | 0.500 |
Why?
| | RNA, Helminth | 3 | 2013 | 17 | 0.490 |
Why?
| | Transcription Initiation Site | 2 | 2013 | 40 | 0.470 |
Why?
| | Melanoma | 1 | 2020 | 629 | 0.460 |
Why?
| | Operon | 2 | 2011 | 59 | 0.460 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 524 | 0.430 |
Why?
| | Trans-Splicing | 2 | 2013 | 15 | 0.390 |
Why?
| | Thymus Gland | 2 | 2023 | 296 | 0.370 |
Why?
| | DNA, Recombinant | 1 | 2010 | 41 | 0.370 |
Why?
| | Mice | 16 | 2023 | 14916 | 0.360 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2011 | 82 | 0.350 |
Why?
| | Animals | 22 | 2023 | 31761 | 0.320 |
Why?
| | Transplantation, Heterologous | 2 | 2018 | 183 | 0.280 |
Why?
| | Neoplasms | 2 | 2020 | 2105 | 0.280 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1745 | 0.240 |
Why?
| | Immunophenotyping | 3 | 2019 | 275 | 0.220 |
Why?
| | Genes, Helminth | 3 | 2013 | 26 | 0.220 |
Why?
| | Hyaluronan Receptors | 2 | 2020 | 91 | 0.210 |
Why?
| | Hedgehog Proteins | 2 | 2014 | 173 | 0.210 |
Why?
| | Pluripotent Stem Cells | 1 | 2023 | 63 | 0.200 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 142 | 0.200 |
Why?
| | SOXB1 Transcription Factors | 2 | 2020 | 61 | 0.180 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 42 | 0.170 |
Why?
| | Radiotherapy Dosage | 2 | 2020 | 245 | 0.170 |
Why?
| | Stem Cell Niche | 1 | 2019 | 42 | 0.160 |
Why?
| | Humans | 22 | 2023 | 114714 | 0.160 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 232 | 0.160 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 182 | 0.160 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 70 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 664 | 0.160 |
Why?
| | RNA, Messenger | 3 | 2016 | 2557 | 0.150 |
Why?
| | Peptides, Cyclic | 1 | 2020 | 253 | 0.150 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 31 | 0.150 |
Why?
| | Cell Differentiation | 4 | 2023 | 1699 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2020 | 197 | 0.140 |
Why?
| | Mice, Nude | 5 | 2018 | 635 | 0.140 |
Why?
| | Telomere | 1 | 2019 | 202 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 147 | 0.140 |
Why?
| | Cell Proliferation | 4 | 2019 | 2196 | 0.140 |
Why?
| | Cell Communication | 1 | 2018 | 279 | 0.140 |
Why?
| | Cell Line, Tumor | 6 | 2020 | 2725 | 0.140 |
Why?
| | Veratrum Alkaloids | 2 | 2014 | 17 | 0.140 |
Why?
| | Mice, Knockout | 3 | 2018 | 2582 | 0.140 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2016 | 27 | 0.140 |
Why?
| | ErbB Receptors | 3 | 2016 | 560 | 0.130 |
Why?
| | Radiometry | 1 | 2015 | 42 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2015 | 68 | 0.130 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 119 | 0.120 |
Why?
| | Neoplasms, Experimental | 1 | 2015 | 152 | 0.120 |
Why?
| | Stromal Cells | 1 | 2014 | 96 | 0.120 |
Why?
| | Mice, Inbred NOD | 3 | 2023 | 561 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2014 | 92 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 2 | 2014 | 617 | 0.110 |
Why?
| | Exercise | 1 | 2023 | 1643 | 0.110 |
Why?
| | Base Sequence | 3 | 2013 | 2118 | 0.100 |
Why?
| | Sulfones | 1 | 2013 | 97 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1147 | 0.100 |
Why?
| | Glycine | 1 | 2013 | 152 | 0.100 |
Why?
| | Transcriptome | 2 | 2016 | 727 | 0.100 |
Why?
| | Biomarkers | 2 | 2019 | 3414 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1053 | 0.100 |
Why?
| | Gene Components | 1 | 2011 | 5 | 0.090 |
Why?
| | Genome, Helminth | 1 | 2010 | 3 | 0.090 |
Why?
| | RNA, Spliced Leader | 1 | 2010 | 12 | 0.090 |
Why?
| | RNA Splice Sites | 1 | 2011 | 34 | 0.090 |
Why?
| | Obesity | 2 | 2020 | 2513 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2013 | 436 | 0.090 |
Why?
| | Stem Cells | 1 | 2014 | 546 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2020 | 330 | 0.090 |
Why?
| | RNA Splicing | 1 | 2010 | 245 | 0.080 |
Why?
| | Signal Transduction | 4 | 2016 | 4521 | 0.080 |
Why?
| | Intestinal Mucosa | 1 | 2013 | 530 | 0.080 |
Why?
| | Cytokines | 1 | 2016 | 1843 | 0.080 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1635 | 0.080 |
Why?
| | Models, Biological | 1 | 2015 | 1630 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 928 | 0.080 |
Why?
| | DNA Nucleotidyltransferases | 1 | 2008 | 11 | 0.080 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 128 | 0.070 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 388 | 0.070 |
Why?
| | Epithelial Cells | 2 | 2023 | 955 | 0.070 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2791 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2018 | 854 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1361 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2021 | 3890 | 0.060 |
Why?
| | Papillomaviridae | 2 | 2016 | 102 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 552 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 359 | 0.050 |
Why?
| | Antigens, CD | 2 | 2016 | 443 | 0.050 |
Why?
| | Cetuximab | 2 | 2013 | 91 | 0.050 |
Why?
| | Organoids | 1 | 2023 | 74 | 0.050 |
Why?
| | Physical Fitness | 1 | 2023 | 179 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 195 | 0.050 |
Why?
| | Life Style | 1 | 2023 | 430 | 0.050 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 23 | 0.050 |
Why?
| | Feedback, Physiological | 1 | 2020 | 68 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 351 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 117 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 188 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 190 | 0.040 |
Why?
| | DNA Repair | 1 | 2020 | 186 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2015 | 2762 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 368 | 0.040 |
Why?
| | Monocytes | 1 | 2020 | 503 | 0.040 |
Why?
| | DNA Damage | 1 | 2020 | 357 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 445 | 0.040 |
Why?
| | Cell Cycle | 1 | 2020 | 543 | 0.040 |
Why?
| | Retinal Dehydrogenase | 1 | 2016 | 41 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2018 | 180 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2013 | 1133 | 0.030 |
Why?
| | Absorption, Radiation | 1 | 2015 | 3 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2016 | 58 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1176 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 642 | 0.030 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2016 | 134 | 0.030 |
Why?
| | Mutation | 2 | 2018 | 3349 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 176 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 936 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 21 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2014 | 15 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 36 | 0.030 |
Why?
| | Cell Division | 1 | 2016 | 759 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 863 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 312 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2013 | 22 | 0.030 |
Why?
| | Cross-Priming | 1 | 2013 | 19 | 0.030 |
Why?
| | Receptors, Chemokine | 1 | 2013 | 43 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2013 | 57 | 0.030 |
Why?
| | Antigens, CD1 | 1 | 2013 | 57 | 0.030 |
Why?
| | Mice, SCID | 1 | 2014 | 320 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 115 | 0.030 |
Why?
| | Th17 Cells | 1 | 2013 | 58 | 0.030 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 14 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 213 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 241 | 0.030 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 20 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | Integrins | 1 | 2013 | 79 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 77 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 1958 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 168 | 0.030 |
Why?
| | 5' Untranslated Regions | 1 | 2013 | 51 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2013 | 81 | 0.030 |
Why?
| | Female | 4 | 2020 | 59485 | 0.030 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 36 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 61 | 0.030 |
Why?
| | Fetal Blood | 1 | 2014 | 270 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 305 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 268 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2013 | 218 | 0.030 |
Why?
| | Gene Silencing | 1 | 2013 | 172 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2013 | 460 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 343 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 604 | 0.020 |
Why?
| | Glycoproteins | 1 | 2013 | 304 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2321 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 878 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1521 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 743 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 812 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2973 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1690 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2384 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2013 | 342 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1151 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2013 | 728 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1086 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 262 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 610 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2369 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 530 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 642 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1468 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1951 | 0.020 |
Why?
| | Tetanus Toxin | 1 | 2008 | 5 | 0.020 |
Why?
| | Heat-Shock Response | 1 | 2008 | 46 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2008 | 215 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2008 | 176 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2008 | 165 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 514 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 9089 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1528 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 373 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2008 | 337 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1895 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 4710 | 0.020 |
Why?
| | Male | 2 | 2020 | 55558 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 12512 | 0.010 |
Why?
| | Aged | 1 | 2019 | 19079 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 26746 | 0.010 |
Why?
| | Adult | 1 | 2014 | 30543 | 0.010 |
Why?
|
|
Morton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|